Karuna Therapeutics Sees Breakthrough In Schizophrenia Drug
Karuna Therapeutics' top-experimental schizophrenia drug significantly reduced symptoms in a late-stage trial but there were concerns that it could cause hypertension in patients.
The Centers for Disease Control and Prevention announced an urgent need to increase vaccination coverage in response to rising respiratory disease levels.